KalVista Pharmaceuticals (KALV) Total Non-Current Liabilities (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Total Non-Current Liabilities data on file, last reported at $136.3 million in Q3 2025.

• For the quarter ending Q3 2025, Total Non-Current Liabilities rose 2633.36% year-over-year to $136.3 million; the trailing twelve-month figure through Jul 2025 stood at $136.3 million (up 2633.36% YoY), and the FY2025 full-year result was $110.2 million, up 1732.29% from the prior year.
• Total Non-Current Liabilities climbed to $136.3 million in Q3 2025, from $110.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $136.3 million in Q3 2025 to a low of $1.1 million in Q1 2021.
• A 5-year average of $24.8 million and a median of $6.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities plunged 67.22% in 2021 and jumped 2633.36% in 2025, its largest moves.
• Tracing KALV's Total Non-Current Liabilities over 5 years: stood at $6.2 million in 2021, then grew by 23.79% to $7.7 million in 2022, then declined by 15.04% to $6.5 million in 2023, then jumped by 1825.25% to $126.0 million in 2024, then gained by 8.18% to $136.3 million in 2025.
• Business Quant data shows KALV's Total Non-Current Liabilities at $136.3 million in Q3 2025, $110.2 million in Q2 2025, and $126.0 million in Q4 2024.